1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThe 2027 application is downloadable from the page; 2026 grants have already been awarded. No specific deadline date is stated on the page.
PBCC Research Grants is sponsored by PA Breast Cancer Coalition. The PA Breast Cancer Coalition awards grants to Pennsylvania scientists focused on finding breakthroughs in the detection and treatment of breast cancer. The program has a strong interest in research improving immunotherapy for breast cancer.
Get alerted about grants like this
Get emailed when new opportunities from “PA Breast Cancer Coalition” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
PBCC Research Grants - PA Breast Cancer Coalition To date, the PA Breast Cancer Coalition has awarded more than $6. 6 million to Pennsylvania breast cancer researchers, bringing us one step closer to “finding a cure now… so our daughter don’t have to. ” Apply now for a 2027 PA Breast Cancer Coalition research grant!
The PA Breast Cancer Coalition is now accepting applications for breast cancer research grants of $100,000 each for the period of January 1, 2027 – December 31, 2027 . Each year, the PBCC awards grants to Pennsylvania scientists focused on finding breakthroughs in the detection and treatment of breast cancer.
opens in a new window Download the 2027 research grant application opens in a new window Download the budget Interested in serving on our Research Grants Review Committee? Click here. Congratulations, 2026 PBCC Research Grant Awardees!
This study investigates how dormant breast cancer cells survive treatment and later return as therapy-resistant metastatic tumors. The team discovered that the protein SEPP1 plays a key role in helping these cells survive and driving tumor recurrence. Patients whose tumors gain extra copies of the SEPP1 gene tend to have poorer outcomes.
Experiments show that targeting SEPP1 can eliminate dormant cancer cells and prevent tumor recurrence in mice. Understanding the role of SEPP1 provides a promising path to develop new therapies aimed at stopping metastatic breast cancer and improving patient survival. Learn more about Dr. Chodosh’s research This study aims to use a novel imaging technique, DNP-13C-MRSI, to detect and measure dormant breast cancer cells.
Researchers will also test whether this method can predict tumor recurrence after therapy. The findings will guide early clinical trials in patients with invasive breast cancer, exploring its potential to forecast treatment response, recurrence risk, and long-term outcomes.
This work represents the first use of hyperpolarized MRI to study breast cancer dormancy and could become a powerful tool for improving prognosis and personalizing therapy to reduce the risk of cancer returning. Learn more about Dr. Edmonds’s research Thomas Jefferson University This research focuses on understanding why some triple-negative breast cancer (TNBC) cells resist new targeted treatments.
TNBC is an aggressive cancer with high relapse rates, frequent metastasis, and poor survival, often driven by mutations in the p53 gene that make tumor cells more aggressive. The team discovered that p53-mutated TNBC cells rely on a protein called MDM2 to survive. A new compound has been developed to destroy MDM2 and kill these cancer cells.
This study aims to uncover how TNBC cells might develop resistance to this treatment, ultimately guiding more effective therapies for patients. Learn more about Dr. Eischen’s research This research focuses on developing more precise breast cancer treatments by targeting mechanisms that drive tumor growth and spread. The studies investigate dielectric barrier discharge plasma (DBDP), a form of non-thermal plasma, as a potential therapy.
DBDP can activate immune responses against both treated tumors and untreated metastatic tumors, making it a patient-specific immunotherapy. The research explores how DBDP triggers tumor-specific immune responses and how it can be combined with other therapies for greater effectiveness. These studies aim to establish proof of concept for DBDP and lay the foundation for new breast cancer treatments.
Learn more about Dr. Krebs’s research Thomas Jefferson University This research focuses on improving immunotherapy for breast cancer, which often fails because tumors block immune cells from accessing the nutrients they need to fight cancer. Breast tumors consume the nutrient acetate, depriving immune cells. A drug has been developed that blocks tumors from using acetate while leaving it available for immune cells.
In preclinical studies, this approach activates immune cells to target tumors and is effective across multiple breast cancer subtypes. These findings could lead to more effective, less toxic treatments and support clinical trials combining acetate metabolism inhibitors with immune cell therapies like CAR-T. Learn more about Dr. Schug’s reserach The PA Breast Cancer Coalition awards $500,000 in Research Grants in 2026.
To date, the program has awarded more than $6. 6 million to outstanding Pennsylvania scientists. Because of your support, we are able to help Pennsylvania breast cancer researchers get their innovative ideas off the ground.
Make a gift to the future of breast cancer treatment today. opens in a new window Donate Now PBCC Research Grant Reviewers Wanted Help us select future PA Breast Cancer Coalition Research Grant winners! Give today to empower survivors, advance research, and strengthen communities battling breast cancer.
Your gift today brings us closer to a future free of breast cancer—thank you for making an impact.
Scoring criteria used to review proposals for this grant.
According to the current listing, eligibility includes: Pennsylvania scientists focused on breast cancer research, including immunotherapy. Confirm the full requirements in the official notice before applying.
The current listing shows $100,000 per grant. Verify award ceilings, matching requirements, and allowable costs in the official notice.
PBCC Research Grants is funded by PA Breast Cancer Coalition. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Pennsylvania. If your organization operates elsewhere, check the official notice for location requirements.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
The Bureau of Democracy, Human Rights, and Labor has opened NOFO DFOP0019327, a $2.96 million single-award competition to build a global coalition countering transnational repression — the practice of governments reaching across borders to silence dissidents, journalists, and diaspora communities. Applications from nonprofits, think tanks, and NGOs are due August 12, 2026. Here is what transnational repression is, what DRL is actually buying, who is eligible, and how to build a competitive proposal for a winner-take-all award.
Read articleOn July 14, 2026, NSF named 12 new Regional Innovation Engines across 20 states, each starting with $15 million over two years and eligible for up to $160 million across a decade. But the Engines program is not a research grant — it is a bet on a regional coalition's ability to convert federal seed money into private matching capital. The first cohort turned $135 million into over $2 billion in commitments. Here is how the milestone-gated structure actually works, who wins these awards, and what a region needs in place long before the next competition opens.
Read articleTen foundations — Ford, MacArthur, Mellon, Mozilla, Omidyar, Doris Duke, Lumina, Kapor, Packard, and Siegel — committed $500M over five years to Humanity AI in October 2025. On May 12, 2026, the collaborative made its inaugural bet: $18M to nine organizations at $500K each plus a $3M AI Civics initiative led by Data & Society and Digital Public Library of America. A $10M open call lands this summer. Here's who got funded, who was conspicuously left out, what the open-call criteria are likely to look like, and how mission-aligned nonprofits should position now.
Read article